Videos

A pharmacist explored how recent NCCN guideline updates leverage ctDNA MRD testing to guide adjuvant immunotherapy and improve EFS in bladder cancer.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, explained how an all-oral AML regimen impacts infusion center logistics and patient visits.

A pharmacist discussed the operational hurdles, payer coverage rates, and lack of standardized surveillance protocols for bladder cancer ctDNA testing.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, discussed how fast oral DEC-C plus venetoclax may replace IV HMA regimens in AML.

Sara Hurvitz, MD, FACP, explained how to prevent and manage stomatitis in patients with breast cancer receiving the newly approved gedatolisib.

Dr. Ajai Chari and Dr. Rahul Banerjee explore future directions for talquetamab in relapsed/refractory multiple myeloma (RRMM), focusing on emerging combination strategies designed to enhance the activity of T-cell–redirecting therapies.

The panel discusses how to apply real-world evidence to frontline regimen selection in advanced hepatocellular carcinoma (HCC).

Midhun Malla, MD, presents real-world data for Team Deep-Dish Pizza, reviewing a multicenter retrospective study comparing frontline atezolizumab plus bevacizumab with durvalumab-based therapy in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee discuss the evolving understanding of neurologic adverse events associated with GPRC5D-directed therapies in relapsed/refractory multiple myeloma (RRMM).

Sara Hurvitz, MD, FACP, discussed the IV formulation of gedatolisib and its favorable toxicity profile compared with oral PI3K inhibitors in breast cancer.

Sara Hurvitz, MD, FACP, explained why the FDA approval of gedatolisib is practice changing for patients with HR+/HER2– metastatic breast cancer.

How CML doctors plan treatment-free remission from day one, aiming for MR4.5, boosting adherence, and timing TKI stopping to reduce relapse.

Sikander Ailawadhi, MD, says shorter subcutaneous administration times could free up capacity at busy infusion centers.

The subcutaneous isatuximab approval gives patients “many more options” for anti-CD38 therapy, according to Sikander Ailawadhi, MD.

Dr. Shadman notes that discussions about elderly patients with CLL increasingly focus on patients aged 80 years and older, given the disease's median diagnosis age of 68 to 70 years.

Experts weigh TDxd’s real-world tolerability, trial gaps, and biomarkers guiding escalation or de-escalation in HER2+ breast cancer care.

Andrew Lipsky, MD, reviews the ELEVATE-TN trial supporting acalabrutinib approval in frontline CLL, demonstrating superiority over chlorambucil-obinutuzumab.

Clinicians share practical tips to spot T-DXd lung toxicity early, manage nausea and fatigue, and counsel on hair loss options.

Transitioning into a discussion of emerging clinical evidence, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine the efficacy endpoints that are most meaningful when evaluating BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).

Learn how to spot and treat cemiplimab immune side effects early, and why multidisciplinary teams improve advanced cutaneous SCC outcomes.

The panel discusses a 52-year-old patient with metastatic TNBC including lung lesions and previously treated stable brain metastases, presenting for first-line treatment recommendations.

Panelists agreed that subcutaneous amivantamab represents meaningful progress over the IV formulation, nearly eliminating infusion reactions, reducing dosing frequency to every four weeks, and lowering high-grade dermatologic toxicity, although grade 1-2 rash and the burden of the COCOON prophylaxis regimen remain relevant considerations for patients.

Dr. Hamid presents an 86-year-old retired construction worker with diabetes, hypertension, and prior basal cell carcinoma, now with a 2.8 cm facial CSCC lesion and imaging-confirmed pulmonary metastases.

Dr. Ajai Chari and NP Samantha Shenoy discuss practical aspects of managing newly diagnosed multiple myeloma (NDMM) in routine clinical practice, emphasizing the importance of individualized care throughout the treatment journey. The faculty review strategies for monitoring patients receiving long-term therapy, addressing treatment-related adverse events, and maintaining adherence through proactive supportive care and patient education. The conversation highlights the value of multidisciplinary collaboration, including the role of advanced practice providers in coordinating care, reinforcing treatment expectations, and facilitating shared decision-making. Dr. Chari and NP Shenoy also discuss how ongoing communication with patients can help manage quality-of-life concerns while supporting treatment continuity and long-term disease control. The discussion underscores the importance of integrating clinical trial evidence with practical experience to optimize frontline management and deliver patient-centered care for individuals living with NDMM.

Dr. Ajai Chari and NP Samantha Shenoy conclude the discussion by reflecting on the evolving management of newly diagnosed multiple myeloma (NDMM) and the clinical implications of recent advances in CD38-directed therapy. The faculty summarize how long-term follow-up from contemporary clinical trials has reinforced the importance of achieving deep responses while balancing efficacy, safety, and patient-centered treatment goals. The conversation explores the growing role of minimal residual disease (MRD) assessment, ongoing therapy, and individualized treatment duration as areas of continued clinical interest, while emphasizing that treatment decisions should remain tailored to each patient's overall health status and preferences. Dr. Chari and NP Shenoy also discuss practical considerations for multidisciplinary care, patient education, and longitudinal follow-up, highlighting the importance of shared decision-making as frontline treatment strategies continue to evolve and additional long-term evidence becomes available for patients with NDMM.

The debate centered on CNS efficacy comparisons between MARIPOSA and FLAURA2, with the key distinction being that MARIPOSA mandated serial brain MRIs for all patients, enabling full intracranial PFS analysis across all 429 participants, whereas FLAURA2 only required serial imaging in patients with baseline CNS metastases, limiting the robustness of its CNS data.

Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.

Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on how these therapies fit within an increasingly complex treatment landscape.

The panel reviews a 58-year-old patient with HR-positive, HER2-negative metastatic breast cancer progressing after endocrine therapy plus CDK4/6 inhibitor treatment. The patient has hepatic and bone metastases with radiographic and symptomatic progression, ECOG performance status 1, controlled hypertension, and mild dry eye syndrome. She prioritizes maintaining professional activity and independence.

Recurrent facial squamous cell cancer with CLL challenges surgery and radiation; experts weigh immunotherapy, cemiplimab data, and patient goals.